Synthesis and Preclinical Evaluation of <sup>177</sup> Lu-CHX-A”-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma
Mythili Kameswaran(Tata Memorial Hospital), Grace Samuel, Ashutosh Dash(Bhabha Atomic Research Centre), Vikram Gota, Kamal Pathak(Tata Memorial Hospital), Usha Pandey(Bhabha Atomic Research Centre), K.V. Vimalnath(Bhabha Atomic Research Centre), Chetan Dhakan(Tata Memorial Hospital)
Cited by 23
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
|Journal of Clinical Oncology|2017|340
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117